Clinical Trial Update: Dose-finding Study of MCI-196 [Phase 3]

View source ↗

Summary

Phase 3 dose-finding study of MCI-196 sponsored by Tanabe Pharma has been terminated. The trial investigated MCI-196 in chronic kidney disease patients, includi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• MCI-196

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Chronic Kidney Disease, Dialysis | Phase 3 | Status: TERMINATED